Compare CVGI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | CNTX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7M | 102.9M |
| IPO Year | 2004 | 2021 |
| Metric | CVGI | CNTX |
|---|---|---|
| Price | $1.60 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 93.0K | ★ 485.5K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $657,532,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.49 |
| 52 Week High | $2.59 | $1.61 |
| Indicator | CVGI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 43.47 |
| Support Level | $1.57 | $0.99 |
| Resistance Level | $1.67 | $1.10 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.00 | 24.37 |
Commercial Vehicle Group Inc is a provider of systems, assemblies, and components to the commercial vehicle market and the electric vehicle markets. It delivers solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities. Its operating segments are Vehicle Solutions, Electrical Systems, and Aftermarket and Accessories. The company makes the majority of its revenue from Vehicle Solutions. The group generates revenue from its products including seating systems, plastic components, electrical wire harnesses, mirrors, wipers, and other accessories. Its geographic regions are North America, Europe and Asia-Pacific.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.